ARTICLE | Finance
Buysiders eye 2022 as the year of immuno-oncology’s next big act
High hopes for catalysts brewing for years have investors expecting a new era, and neurology may be on the upswing too
January 8, 2022 12:08 AM UTC
Cancer immunotherapy is poised for long-awaited breakthroughs in 2022, which promises a full slate of regulatory and clinical milestones that could re-ignite buysider excitement while drawing in generalists.
For the last seven years, the immuno-oncology market has remained dominated by the first PD-1 blockers to gain approval, despite a massive influx of new companies and pharma resources aimed at identifying the next immunotherapy success story...
BCIQ Company Profiles